Chronic Myelogenous Leukemia Treatment Market 2032: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, NICE Approvals, Prevalence, Therapies and Companies by DelveInsight

Chronic Myelogenous Leukemia Companies are Enliven Therapeutics, Terns Pharmaceuticals, Ascentage Pharma, Novartis, M.D. Anderson Cancer Center, Kartos Therapeutics, Groupe Francophone des Myelodysplasies, University of Jena, Takeda, Il-Yang Pharm. Co., Ltd., Shenzhen TargetRx, Inc., Bristol-Myers Squibb, Astex Pharmaceuticals, Inc., and others.
(Albany, USA) DelveInsight's "Chronic Myelogenous Leukemia Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Chronic Myelogenous Leukemia, historical and forecasted epidemiology as well as the Chronic Myelogenous Leukemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Chronic Myelogenous Leukemia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Chronic Myelogenous Leukemia market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Chronic Myelogenous Leukemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Chronic Myelogenous Leukemia market.

To Know in detail about the Chronic Myelogenous Leukemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Myelogenous Leukemia Market Forecast [https://www.delveinsight.com/report-store/chronic-myelogenous-leukemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key facts of the Chronic Myelogenous Leukemia Market Report:

* The Chronic Myelogenous Leukemia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
* In February 2025, Cipla has obtained final approval from the US FDA for its Nilotinib Capsules (50 mg, 150 mg, 200 mg) for the treatment of Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML). The product is anticipated to be launched in the US during FY2025-26.
* In November 2024, Marks Shorla Oncology has announced FDA approval for imatinib (Imkeldi), the first oral liquid tyrosine kinase inhibitor (TKI) authorized for treating multiple cancers, including gastrointestinal stromal tumors (GIST), myelodysplastic syndromes (MDS), myeloproliferative disease (MPD), chronic Myelogenous leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
* In November 2024, The U.S. Food and Drug Administration (FDA) has approved a reformulated version of nilotinib (Danziten) for adults with newly diagnosed Philadelphia chromosome-positive chronic Myelogenous leukemia (CML) in the chronic phase. The approval also covers adult patients in the chronic or acute phase of CML who have shown resistance or intolerance to previous treatments, including imatinib.
* In October 2024, Novartis has obtained accelerated approval from the U.S. Food and Drug Administration (FDA) for Scemblix (asciminib) for the treatment of adults with newly diagnosed Philadelphia chromosome-positive chronic Myelogenous leukemia in the chronic phase (Ph+ CML-CP).
* In January 2024, Terns Pharmaceuticals expected significant proof-of-concept results for TERN-701 (for Chronic Myelogenous Leukemia) by the latter half of 2024.
* In January 2024, Novartis reported favorable outcomes from the primary analysis of ASC4FIRST, a critical Phase III trial that compared SCEMBLIX against the preferred tyrosine kinase inhibitor (TKI) treatment chosen by investigators. This study focused on newly diagnosed patients with Philadelphia chromosome-positive chronic Myelogenous leukemia in the chronic phase.
* According to projections by the American Cancer Society, around 9,280 individuals in the United States are expected to be diagnosed with CML in 2024, including 5,330 cases in men and 3,950 cases in women.
* According to the NICE UK, CML has an annual incidence of 4.2 cases per 100,000 individuals. Additionally, CML accounts for only 5% of childhood leukemia cases. Moreover, it is noted that 85-90% of patients are diagnosed during the chronic phase of the disease.
* In 2022, based on SEER data, it is projected that there will be approximately 8,860 new cases of CML in the United States.
* Key Chronic Myelogenous Leukemia Companies: Enliven Therapeutics, Terns Pharmaceuticals, Ascentage Pharma, Novartis, M.D. Anderson Cancer Center, Kartos Therapeutics, Groupe Francophone des Myelodysplasies, University of Jena, Takeda, Il-Yang Pharm. Co., Ltd., Shenzhen TargetRx, Inc., Bristol-Myers Squibb, Astex Pharmaceuticals, Inc., and others
* Key Chronic Myelogenous Leukemia Therapies: ELVN-001, TERN-701, HQP1351, ABL001, Asciminib, KRT-232, Venetoclax, Imatinib, Ponatinib, Radotinib, TGRX-678, Dasatinib, Azacitidine, and others
* The Chronic Myelogenous Leukemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Myelogenous Leukemia pipeline products will significantly revolutionize the Chronic Myelogenous Leukemia market dynamics.

Chronic Myelogenous Leukemia Overview

Chronic Myelogenous Leukemia (CML) is a rare type of blood cancer that originates in the bone marrow and leads to the uncontrolled growth of Myelogenous cells. Chronic Myelogenous Leukemia is primarily associated with a genetic mutation known as the Philadelphia chromosome, which results in the BCR-ABL fusion gene that drives cancer progression. Chronic Myelogenous Leukemia often progresses slowly and may not show symptoms in its early stages, making timely diagnosis critical. Common symptoms of Chronic Myelogenous Leukemia include fatigue, unexplained weight loss, night sweats, and an enlarged spleen.

The global Chronic Myelogenous Leukemia market is expanding due to advancements in targeted therapies, especially tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib. These therapies have significantly improved survival rates and quality of life for Chronic Myelogenous Leukemia patients. Ongoing clinical trials are exploring newer treatment options and combination therapies for resistant or advanced Chronic Myelogenous Leukemia cases.

Despite treatment progress, Chronic Myelogenous Leukemia poses challenges such as drug resistance, long-term side effects, and high treatment costs. Increased awareness, early screening, and continuous innovation in drug development remain key to managing Chronic Myelogenous Leukemia effectively. The future outlook for Chronic Myelogenous Leukemia is promising with emerging therapies on the horizon.

Get a Free sample for the Chronic Myelogenous Leukemia Market Forecast, Size & Share Analysis Report: Chronic Myelogenous leukemia Treatment Market [https://www.delveinsight.com/sample-request/chronic-myelogenous-leukemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Chronic Myelogenous Leukemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Myelogenous Leukemia Epidemiology Segmentation:

The Chronic Myelogenous Leukemia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

* Total Prevalence of Chronic Myelogenous Leukemia
* Prevalent Cases of Chronic Myelogenous Leukemia by severity
* Gender-specific Prevalence of Chronic Myelogenous Leukemia
* Diagnosed Cases of Episodic and Chronic Chronic Myelogenous Leukemia

Download the report to understand which factors are driving Chronic Myelogenous Leukemia epidemiology trends @ Chronic Myelogenous Leukemia Epidemiology Forecast [https://www.delveinsight.com/report-store/chronic-myelogenous-leukemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Chronic Myelogenous Leukemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Myelogenous Leukemia market or expected to get launched during the study period. The analysis covers Chronic Myelogenous Leukemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Myelogenous Leukemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Myelogenous Leukemia Therapies and Key Companies

* ELVN-001: Enliven Therapeutics
* TERN-701: Terns Pharmaceuticals
* HQP1351: Ascentage Pharma
* ABL001: Novartis
* Asciminib: M.D. Anderson Cancer Center
* KRT-232: Kartos Therapeutics
* Venetoclax: Groupe Francophone des Myelodysplasies
* Imatinib: University of Jena
* Ponatinib: Takeda
* Radotinib: Il-Yang Pharm. Co., Ltd.
* TGRX-678: Shenzhen TargetRx, Inc.
* Dasatinib: Bristol-Myers Squibb
* Azacitidine: Astex Pharmaceuticals, Inc.

Discover more about therapies set to grab major Chronic Myelogenous Leukemia market share @ Chronic Myelogenous Leukemia Treatment Landscape [https://www.delveinsight.com/sample-request/chronic-myelogenous-leukemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Chronic Myelogenous Leukemia Market Strengths

* Premium-price agents with superior efficacy such as immunotherapies and kinase inhibitors are expected to dominate the Chronic Myelogenous Leukemia market.
* Novel treatments like SCEMBLIX (asciminib) demonstrate specific targeting of the ABL myristoyl pocket, leading to improved safety and tolerability compared to current standard care.

Chronic Myelogenous Leukemia Market Opportunities

* Currently limited treatment options available for relapsed and refractory cases in Chronic Myelogenous Leukemia.
* Participation in and support for clinical trials provide opportunities to evaluate novel therapies, contributing to advancements in Chronic Myelogenous Leukemia management.

Scope of the Chronic Myelogenous Leukemia Market Report

* Study Period: 2019-2032
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Chronic Myelogenous Leukemia Companies: Enliven Therapeutics (NASDAQ: ELVN), Terns Pharmaceuticals (NASDAQ: TERN), Ascentage Pharma (HKEX: 6855), Novartis (SWX: NOVN), and Takeda (TSE: 4502) are among the key players in the space. Other organizations involved include M.D. Anderson Cancer Center, Kartos Therapeutics, Groupe Francophone des Myelodysplasies, University of Jena, Il-Yang Pharm. Co., Ltd., Shenzhen TargetRx, Inc., Bristol-Myers Squibb (NYSE: BMY), and Astex Pharmaceuticals, and others
* Key Chronic Myelogenous Leukemia Therapies: ELVN-001, TERN-701, HQP1351, ABL001, Asciminib, KRT-232, Venetoclax, Imatinib, Ponatinib, Radotinib, TGRX-678, Dasatinib, Azacitidine, and others
* Chronic Myelogenous Leukemia Therapeutic Assessment: Chronic Myelogenous Leukemia current marketed and Chronic Myelogenous Leukemia emerging therapies
* Chronic Myelogenous Leukemia Market Dynamics: Chronic Myelogenous Leukemia market drivers and Chronic Myelogenous Leukemia market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Chronic Myelogenous Leukemia Unmet Needs, KOL's views, Analyst's views, Chronic Myelogenous Leukemia Market Access and Reimbursement

To know more about Chronic Myelogenous Leukemia companies working in the treatment market, visit @ Chronic Myelogenous Leukemia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/chronic-myelogenous-leukemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Chronic Myelogenous Leukemia Market Report Introduction

2. Executive Summary for Chronic Myelogenous Leukemia

3. SWOT analysis of Chronic Myelogenous Leukemia

4. Chronic Myelogenous Leukemia Patient Share (%) Overview at a Glance

5. Chronic Myelogenous Leukemia Market Overview at a Glance

6. Chronic Myelogenous Leukemia Disease Background and Overview

7. Chronic Myelogenous Leukemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Myelogenous Leukemia

9. Chronic Myelogenous Leukemia Current Treatment and Medical Practices

10. Chronic Myelogenous Leukemia Unmet Needs

11. Chronic Myelogenous Leukemia Emerging Therapies

12. Chronic Myelogenous Leukemia Market Outlook

13. Country-Wise Chronic Myelogenous Leukemia Market Analysis (2019-2032)

14. Chronic Myelogenous Leukemia Market Access and Reimbursement of Therapies

15. Chronic Myelogenous Leukemia Market Drivers

16. Chronic Myelogenous Leukemia Market Barriers

17. Chronic Myelogenous Leukemia Appendix

18. Chronic Myelogenous Leukemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-myelogenous-leukemia-treatment-market-2032-ema-pdma-fda-approval-clinical-trials-medication-epidemiology-nice-approvals-prevalence-therapies-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.